Adrian JohnsonTLDR:
- Chief Accounting Officer of Teva Pharmaceutical Industries, Amir Weiss, sold 31,766 shares of the company on February 1, 2024.
- This is part of a pattern of insider sales, with 12 insider sells and no insider buys recorded over the past year for Teva Pharmaceutical Industries.
- Shares of Teva Pharmaceutical Industries were trading at $12.37 on the day of the insider’s recent sale, resulting in a market cap of $13.633 billion.
- The stock’s price-to-GF-Value ratio stands at 1.44, indicating that the stock is considered significantly overvalued according to the GF Value metric.
Chief Accounting Officer Amir Weiss of Teva Pharmaceutical Industries has sold 31,766 shares of the company on February 1, 2024, according to the SEC Filing. Weiss has been active in the market over the past year, selling a total of 33,747 shares and making no purchase transactions.
Teva Pharmaceutical Industries is a global pharmaceutical company that develops, manufactures, and markets generic and specialty medicines. The company’s portfolio includes treatments for disorders in the central nervous system, pain, respiratory, oncology, and more. It is one of the largest generic drug manufacturers in the world.
The insider transaction history for Teva Pharmaceutical Industries shows a pattern of insider sales, with 12 insider sells recorded over the past year and no insider buys during the same period.
On the valuation front, shares of Teva Pharmaceutical Industries were trading at $12.37 on the day of the insider’s recent sale, resulting in a market cap of $13.633 billion. The stock’s price-to-GF-Value ratio stands at 1.44, indicating that the stock is considered significantly overvalued according to the GF Value metric.
The GF Value is a proprietary intrinsic value estimate from GuruFocus, which is determined by historical trading multiples such as price-earnings ratio, price-sales ratio, price-book ratio, and price-to-free cash flow, along with a GuruFocus adjustment factor based on the company’s historical returns and growth, and future business performance estimates from Morningstar analysts.
This article, generated by GuruFocus, is designed to provide general insights and is not tailored financial advice. Our commentary is rooted in historical data and analyst projections, utilizing an impartial methodology, and is not intended to serve as specific investment guidance. It does not formulate a recommendation to purchase or divest any stock and does not consider individual investment objectives or financial circumstances. Our objective is to deliver long-term, fundamental data-driven analysis. Be aware that our analysis might not incorporate the most recent, price-sensitive company announcements or qualitative information.
